DeLLphi-309

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Jan 8, 2024 → Oct 14, 2026

Cited window

Apr 23, 2025 → Oct 14, 2026

Retrieved

Oct 27, 2026

Title

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)

Registry

NCT06745323

Study IDs

20240092

Sponsor

Amgen

Design

Phase 2 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

252 actual

Start

2025-02-26 actual

Primary completion

2029-08-10 estimated

Primary endpoint

Proportion of participants with confirmed objective response to Tarlatamab

Interventions

1 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a view on biomarker-guided patient selection and subtype-specific treatment in small cell lung cancer.
• –Not yet captured in this edition: a question about financial toxicity in maintenance and subsequent treatment decisions for small cell lung cancer.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –50 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed are not a representative sample of all HCP opinion. Reposts, organizational accounts, repeated summaries and versions of the same discussion must not be counted as independent clinicians or consensus.
• –Some potentially relevant passages were not fully assessed, and discussion using unnamed or differently transcribed study references may be absent. Missing commentary cannot establish lack of interest or concern.
• –No full publication for NCT06745323, protocol or exact tarlatamab regulatory label was available for independent reconciliation. Results, regulatory updates and management practices remain attributed accounts where stated.
• –DeLLphi-309's presented analysis was descriptive, with no hypotheses formally tested. Similarity language does not establish equivalence, and numerical differences do not establish inferiority.
• –Survival follow-up was approximately nine months in the accounts discussed. Unreached or non-estimable medians do not establish schedule-specific treatment success.
• –Delivery and hospitalization statements come from different dates, settings and purposes. They should not be combined into a single current administration standard or interpreted as evidence of a change of mind.
• –Clinical roles are not independently confirmed for several named contributors. A confirmed name or account identity is not confirmation of clinical credentials; the advocate perspective is distinguished from HCP commentary.
• –Some source passages do not establish who spoke. Their views remain anonymous, and named passages elsewhere do not resolve that uncertainty.
• –Earlier Phase 3, single-arm or alternative-treatment observations are not DeLLphi-309 results. No schedule-specific CNS conclusion or direct tarlatamab-versus-ADC comparison can be drawn from these discussions.
• –One duration-of-response value in the press-briefing transcript is unclear. The report does not infer a corrected value from that transcript.

How reports are built and checked: Methods.

Last checked for new commentary Oct 27, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "DeLLphi-309" (NCT06745323), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "dellphi-309-06745323". If you cannot make requests, read https://www.erudio.com/reports/dellphi-309-nct06745323.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06745323", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06745323 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/dellphi-309-nct06745323.json
curl https://www.erudio.com/reports/dellphi-309-nct06745323.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "dellphi-309-06745323" })